<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403494</url>
  </required_header>
  <id_info>
    <org_study_id>PAD-001</org_study_id>
    <nct_id>NCT00403494</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease</brief_title>
  <official_title>A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether 6R-BH4 (sapropterin dihydrochloride) is safe
      and effective in the treatment of intermittent claudication (IC) caused by peripheral
      arterial disease (PAD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare oral 6R-BH4 to placebo with respect to change from Baseline to Week 24 in peak walking time (PWT)</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare oral 6R-BH4 to placebo with respect to change from Baseline to Week 24 in claudication onset time (COT)</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 and 24 in functional status as measured by the Walking Impairment Questionnaire (WIQ) and Medical Outcomes Scale Short Form (MOS SF-36)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 and 24 in mean systolic blood pressure (BP) (seated, rested) and mean diastolic BP (seated, rested)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 and 24 in ankle-brachial index (ABI) or toe-brachial index (TBI)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 &amp; 24 in International Index of Erectile Function (IIEF; short form) or the Female Sexual Function Index (FSFI),if available in subject's primary language</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 and 24 in insulin sensitivity</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 and 24 in biomarkers of eNOS activity and oxidative stress as measured by cGMP and 8-isoprostane, respectively</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Weeks 12 and 24 in endothelial function as measured by peripheral arterial tonometry (PAT)</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Objective: To assess the safety of oral dosing of 6R-BH4</measure>
    <time_frame>Baseline, Week 0, 1, 2, 4, 8, 12, 16, 20, 24, 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tertiary Outcome: To compare oral 6R-BH4 to placebo with respect to change from Baseline to Week 12 in PWT and COT</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Intermittent Claudication</condition>
  <arm_group>
    <arm_group_label>6R-BH4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg/day of 6R-BH4, divided into two doses each day, for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be administered in the same manner as that of the investigational product, 6R-BH4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6R-BH4 + Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg/day of 6R-BH4, divided into two doses, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Vitamin C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for 6R-BH4 (sapropterin dihydrochloride)</intervention_name>
    <description>Placebo to be administered in the same manner as that of the investigational product for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6R-BH4 (sapropterin dihydrochloride)</intervention_name>
    <description>800 mg/day 6R-BH4 tablets, divided into two doses, administered orally for 24 weeks</description>
    <arm_group_label>6R-BH4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6R-BH4 (sapropterin dihydrochloride)</intervention_name>
    <description>800 mg/day of 6R-BH4 tablets, divided into two doses, administered orally, plus 1000mg/day Vitamin C caplets, divided into two doses, administered orally for 24 weeks</description>
    <arm_group_label>6R-BH4 + Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for 6R-BH4 (sapropterin dihydrochloride)</intervention_name>
    <description>Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks</description>
    <arm_group_label>Placebo + Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 40 years and no more than 80 years old

          -  A 6-month (or longer) history of walking limitation because of IC, severity of which
             has not changed in the past 3 months

          -  Diagnosis of PAD secondary to atherosclerosis, with PAD documented at Screening by one
             of the following criteria:

               1. Resting ABI &lt; 0.9 in at least one leg

               2. If resting ABI is 0.9-1.0, minimum post-exercise drop in ABI of at least 25% in
                  at least one leg

               3. If resting ABI is &gt; 1.3 (indicating non-compressible vessels), vascular etiology
                  documented by toe-brachial index (TBI) &lt; 0.7 in at least one leg

          -  On Gardner graded treadmill protocol, PWT of at least 1 minute, but no more than 12
             minutes

          -  Variation in PWT between two consecutive screening treadmill tests less than or equal
             to 25%

          -  If currently receiving treatment with or taking any of the following, willing and able
             to discontinue for 30 days before Screening and throughout the entire study (including
             the follow-up period): phosphodiesterase (PDE) 5 inhibitor (eg, Viagra®, Cialis®,
             Levitra®, or Revatio™), any PDE 3 inhibitor (eg, cilostazol, milrinone, or
             vesnarinone), pentoxifylline (Trental®), nitrates, L-arginine, ginkgo biloba, or
             HeartBar

          -  For the approximately 50% of subjects enrolled to receive vitamin C with study drug or
             placebo, subjects must be willing to discontinue taking vitamin C supplements or a
             multivitamin containing vitamin C during study.

          -  Antihypertensive therapy, cholesterol-lowering therapy (eg, statins), and diabetic
             therapy (if applicable) has been stable for 30 days prior to Screening.

          -  Has not changed smoking or exercise habits in 30 days prior to randomization and is
             unlikely to do so during the study period

          -  Willing and able to provide written, signed informed consent after the nature of the
             study has been explained and prior to any research-related procedures

          -  Willing and able to comply with all study-related procedures

          -  Sexually active subjects must be willing to use an acceptable method of contraception
             while participating in the study

          -  Females of childbearing potential must have a negative pregnancy test at Screening and
             be willing to have additional pregnancy tests during the study

        Exclusion Criteria:

          -  Critical leg ischemia, manifested by pain at rest, ulceration, gangrene, or leg
             amputation

          -  Surgical intervention to alleviate symptoms of claudication (eg, vascular
             reconstruction, sympathectomy) within 6 months or any endovascular interventions or
             cardiovascular surgery within 3 months

          -  Walking limited by reasons other than claudication (eg, arthritis, lung disease,
             exercise-limiting cardiac disease, or skin or foot lesions that limit walking)

          -  Clinically significant ECG change during or after exercise treadmill test at Screening
             or Baseline visit(s)

          -  Myocardial infarction, deep vein thrombosis, or cerebrovascular infarct within 3
             months of Screening

          -  Body mass index &gt; 40 (gross obesity)

          -  Hypertension at Screening, defined as seated mean resting BP value of &gt; 160 mmHg
             systolic, &gt; 110 mmHg diastolic, or both

          -  Hypotension at Screening, defined as seated mean resting BP values of &lt; 100 mmHg
             systolic or &lt; 55 mmHg diastolic, or as clinically significant symptomatic
             (orthostatic) hypotension

          -  Non-atherosclerotic vascular disease (eg, Buerger's disease or popliteal entrapment
             syndrome)

          -  Previous treatment with any formulation of BH4

          -  Known allergy or hypersensitivity to any excipient of 6R-BH4

          -  Concurrent disease or condition that would interfere with study participation or
             safety such as bleeding disorders, history of severe gastrointestinal reflux disease,
             arrhythmia, organ transplant, organ failure, current neoplasm, type 1 diabetes
             mellitus, or serious neurological disorders (including seizures)

          -  Previous treatment with gene therapy or other vascular endothelial growth factor
             (VEGF)-related treatment

          -  Any severe co-morbid condition that would limit life expectancy to less than 6 months

          -  Serum creatinine &gt; 2.0 mg/dL or hepatic enzyme levels more than 2 times the upper
             limit of normal

          -  Concomitant treatment with levodopa

          -  Requirement for concomitant treatment with any drug known to inhibit folate metabolism
             (eg, methotrexate)

          -  Use of any investigational product or device within 30 days prior to Screening, or
             requirement for any investigational agent prior to completion of all scheduled study
             assessments

          -  Pregnant or breastfeeding at Screening or planning to become pregnant (subject or
             partner) at any time during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Nwose, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmrn.com</url>
    <description>BioMarin Pharmaceutical Inc. website</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intermittent Claudication</keyword>
  <keyword>IC</keyword>
  <keyword>Symptomatic Peripheral Arterial Disease</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>PAD</keyword>
  <keyword>6R-BH4</keyword>
  <keyword>BH4</keyword>
  <keyword>sapropterin dihydrochloride</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>NO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

